|

First or third generation EGFR-TKIs Clinical Trials

1 actively recruiting trial

Also known as: Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc.

Pipeline

Phase 4: 1

Top Sponsors

  • Tian Xie1

Indications

  • Adenocarcinoma1
  • Carcinoma1
  • Lung Cancer1
  • Non Small Cell Lung Cancer1
  • Cancer1

Other1 trial

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.